Have you stopped receiving our weekly e-newsletter?

Europe

Author: Joe McAweaneyPublished: 12 July 2018

Prep: Cook: Serves:

Due to recent changes in EU law, you must ‘opt-in’ to continue to receive our e-newsletter

On 25 May 2018 General Data Protection Regulation (GDPR) laws were passed by the European Union, significantly changing the ways in which businesses and public sector organisations must handle data.

The new laws mean that all consumer information held before this date must be deleted, meaning that people must ‘opt-in’ to keep receiving communications from organisations. For Parkinson’s Life, this means that if you want to keep receiving our weekly e-mail newsletter you must let us know – regardless of whether you have signed up in the past or not. Legally, we must delete your data and cannot communicate with you if you have not signed up.

To sign up, please click ‘subscribe’ in the top right hand corner of our website and fill out the form.

We are very proud of the work we do here at Parkinson’s Life, and are looking forward to communicating with as many of you as possible in the future.

Last Month

Next Month

Go Back

Share this story

Comments

Advances

Parkinson’s campaigners win fight to have life-changing drug approved

Drug that can “transform” lives is approved for use in Scotland

Sex and young-onset Parkinson’s

Coping with the impact of Parkinson’s on sexuality at a younger age

Why I launched Nepal’s first Parkinson’s support group

Overcoming tough economic challenges in Nepal

Musical therapy study to receive $20 million in funding

The National Institutes of Health (NIH) is donating US $20 million to a medical trial researching the effects of musical therapy on brain conditions, including Parkinson’s. The trial will be carried out by the Sound Health initiative, a joint partnership between the NIH and The John F Kennedy Center for the Performing Arts. The initiative was created to expand current knowledge of how listening, performing and creating music could be harnessed for health and wellness. Francis S. Collins, director of the NIH, said: “We know that the beat of a metronome can steady the gait of someone with Parkinson’s disease, for example, but we don’t fully understand how that happens. “If we can pinpoint in the brain how music therapy works through the use of imaging and biomarkers, the hope is that we can improve its effectiveness and apply it more broadly to improve the lives of millions of people.”

Researchers develop automated system to diagnose Parkinson’s

In an international study, researchers from the US, Germany and Austria have used a non-invasive MRI method to develop an automated system that can diagnose Parkinson’s. As part of the study – published in medical journal ‘The Lancet Digital Health’ – researchers worked with 1,002 patients and used an imaging method that measures how water molecules diffuse in the brain. This helped them to identify where neurodegeneration is occurring. Researchers hope this will help improve the accuracy of early Parkinson’s diagnoses – which they estimate to be around 58%. Dr David Vaillancourt, who led the study, said: “Our method may help to reduce the number of misdiagnosed cases in the future. Since these diseases require unique treatment plans and different medications, and clinical trials testing new medications require the correct diagnosis, getting it right is important for patient care.”

MJFF announces $10 million competition for Parkinson’s

The Michael J Fox Foundation has launched the ‘Ken Griffin Alpha-synuclein Imaging Competition’ – a US $10 million programme aiming to develop a game-changing tool for Parkinson’s research. As part of the competition, participating teams will compete in a scientific race to build a device that is able to identify alpha-synuclein – a protein closely associated with Parkinson’s. Although almost everyone diagnosed with Parkinson’s has clumps of alpha-synuclein in the brain, these are currently only visible when analysing tissue during autopsies. The competition is named after Ken Griffin, CEO of US investment firm Citadel who has given US $7.5 million funding to the programme. Griffin – whose father has Parkinson’s – said: “If we have the imaging capability to observe the pathology that arises from protein-misfolding in real time, and understand how drugs are impacting people in real time, that would be a major advance.”

All fields required

First name*
Last name*
Email address*
Enter Email Confirm Email
Country of residence*
About me*
- I have Parkinson's disease
- I am a partner / carer / family / friend of someone who has Parkinson's
- I am a healthcare professional with an interest in Parkinson's
- I work for a Parkinson's disease organisation
- Other
CAPTCHA
*
- By proceeding you agree to our
Phone
This field is for validation purposes and should be left unchanged.

Have you stopped receiving our weekly e-newsletter?

Europe

Author: Joe McAweaneyPublished: 12 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Advances

Parkinson’s campaigners win fight to have life-changing drug approved

Health & Fitness

Sex and young-onset Parkinson’s

In my country

Why I launched Nepal’s first Parkinson’s support group

Musical therapy study to receive $20 million in funding

Researchers develop automated system to diagnose Parkinson’s

MJFF announces $10 million competition for Parkinson’s

{title}

Subscribe

Have you stopped receiving our weekly e-newsletter?

Europe

Author: Joe McAweaneyPublished: 12 July 2018

Prep: Cook: Serves:

Last Month

Next Month

Share this story

Comments

Related articles

Advances

Parkinson’s campaigners win fight to have life-changing drug approved

Health & Fitness

Sex and young-onset Parkinson’s

In my country

Why I launched Nepal’s first Parkinson’s support group

Musical therapy study to receive $20 million in funding

Researchers develop automated system to diagnose Parkinson’s

MJFF announces $10 million competition for Parkinson’s

{title}

Subscribe

Sign in